Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Illumina (ILMN) Stock Price
Press coverage about Illumina (NASDAQ:ILMN) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Illumina earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the life sciences company an impact score of 45.4867259402363 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- ETFs with exposure to Illumina, Inc. : September 25, 2017 (finance.yahoo.com)
- Illumina, Inc. (ILMN) Given Average Rating of “Hold” by Analysts (americanbankingnews.com)
- Is It Time To Buy Illumina Inc (ILMN)? (finance.yahoo.com)
- Advice by Analysts to Buy Healthcare Stock: Illumina, Inc. (ILMN) – Street Observer (press release) (streetobserver.com)
- Illumina, Inc. (NASDAQ:ILMN) Stock Traded Above Its 50 Day Moving Average – First News 24 (firstnewspaper24.com)
Shares of Illumina (NASDAQ:ILMN) opened at 201.40 on Tuesday. Illumina has a 12 month low of $119.37 and a 12 month high of $214.34. The company has a market capitalization of $29.40 billion, a price-to-earnings ratio of 40.41 and a beta of 0.81. The firm’s 50-day moving average is $199.76 and its 200 day moving average is $181.17.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business had revenue of $662.00 million during the quarter, compared to analyst estimates of $642.38 million. During the same period last year, the firm posted $0.86 EPS. The company’s revenue was up 10.3% on a year-over-year basis. Equities analysts expect that Illumina will post $3.65 EPS for the current year.
ILMN has been the subject of a number of research analyst reports. Leerink Swann restated an “outperform” rating and set a $225.00 price objective (up previously from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective for the company. in a report on Wednesday, June 21st. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Morgan Stanley restated an “underweight” rating and set a $122.00 price objective (up previously from $115.00) on shares of Illumina in a report on Monday, July 10th. Finally, Canaccord Genuity restated a “hold” rating and set a $170.00 price objective on shares of Illumina in a report on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $182.15.
In other news, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the completion of the transaction, the senior vice president now directly owns 24,908 shares in the company, valued at approximately $5,263,807.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $174.24, for a total value of $25,264.80. Following the transaction, the senior vice president now owns 10,646 shares of the company’s stock, valued at $1,854,959.04. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 175,188 shares of company stock valued at $33,870,937. Insiders own 1.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.